1
|
Protti MP, De Monte L, Monte LD, Di Lullo G, Lullo GD. Tumor antigen-specific CD4+ T cells in cancer immunity: from antigen identification to tumor prognosis and development of therapeutic strategies. ACTA ACUST UNITED AC 2014; 83:237-46. [PMID: 24641502 DOI: 10.1111/tan.12329] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2013] [Indexed: 12/22/2022]
Abstract
CD4(+) T cells comprise a large fraction of tumor infiltrating lymphocytes and it is now established that they may exert an important role in tumor immune-surveillance. Several CD4(+) T cell subsets [i.e. T helper (Th)1, Th2, T regulatory (Treg), Th17, Th22 and follicular T helper (Tfh)] have been described and differentiation of each subset depends on both the antigen presenting cells responsible for its activation and the cytokine environment present at the site of priming. Tumor antigen-specific CD4(+) T cells with different functional activity have been found in the blood of cancer patients and different CD4(+) T cell subsets have been identified at the tumor site by the expression of specific transcription factors and the profile of secreted cytokines. Importantly, depending on the subset, CD4(+) T cells may exert antitumor versus pro-tumor functions. Here we review the studies that first identified the presence of tumor-specific CD4(+) T cells in cancer patients, the techniques used to identify the tumor antigens recognized, the role of the different CD4(+) T cell subsets in tumor immunity and in cancer prognosis and the development of therapeutic strategies aimed at activating efficient antitumor CD4(+) T cell effectors.
Collapse
Affiliation(s)
- M P Protti
- Tumor Immunology Unit, San Raffaele Scientific Institute, Milan, Italy; Division of Immunology, Transplantation and Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy
| | | | | | | | | |
Collapse
|
2
|
Mitić NS, Pavlović MD, Jandrlić DR. Epitope distribution in ordered and disordered protein regions - part A. T-cell epitope frequency, affinity and hydropathy. J Immunol Methods 2014; 406:83-103. [PMID: 24614036 DOI: 10.1016/j.jim.2014.02.012] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2013] [Revised: 02/27/2014] [Accepted: 02/27/2014] [Indexed: 02/08/2023]
Abstract
Highly disordered protein regions are prevalently hydrophilic, extremely sensitive to proteolysis in vitro, and are expected to be under-represented as T-cell epitopes. The aim of this research was to find out whether disorder and hydropathy prediction methods could help in understanding epitope processing and presentation. According to the pan-specific T-cell epitope predictors NetMHCpan and NetMHCIIpan and 9 publicly available disorder predictors, frequency of epitopes presented by human leukocyte antigens (HLA) class-I or -II was found to be more than 2.5 times higher in ordered than in disordered protein regions (depending on the disorder predictor). Both HLA class-I and HLA class-II binding epitopes are prevalently hydrophilic in disordered and prevalently hydrophobic in ordered protein regions, whereas epitopes recognized by HLA class-II alleles are more hydrophobic than those recognized by HLA class-I. As regards both classes of HLA molecules, high-affinity binding epitopes display more hydrophobicity than low affinity-binding epitopes (in both ordered and disordered regions). Epitopes belonging to disordered protein regions were not predicted to have poor affinity to HLA class-II molecules, as expected from disorder intrinsic proteolytic instability. The relation of epitope hydrophobicity and order/disorder location was also valid if alleles were grouped according to the HLA class-I and HLA class-II supertypes, except for the class-I supertype A3 in which the main part of recognized epitopes was prevalently hydrophilic. Regarding specific supertypes, the affinity of epitopes belonging to ordered regions varies only slightly (depending on the disorder predictor) compared to the affinity of epitopes in corresponding disordered regions. The distribution of epitopes in ordered and disordered protein regions has revealed that the curves of order-epitope distribution were convex-like while the curves of disorder-epitope distribution were concave-like. The percentage of prevalently hydrophobic epitopes increases with the enhancement of epitope promiscuity level and moving from disordered to ordered regions. These data suggests that reverse vaccinology, oriented towards promiscuous and high-affinity epitopes, is also oriented towards prevalently hydrophobic, ordered regions. The analysis of predicted and experimentally evaluated epitopes of cancer-testis antigen MAGE-A3 has confirmed that the majority of T-cell epitopes, particularly those that are promiscuous or naturally processed, was located in ordered and disorder/order boundary protein regions overlapping hydrophobic regions.
Collapse
Affiliation(s)
- Nenad S Mitić
- University of Belgrade, Faculty of Mathematics, P.O.B. 550, Studentski trg 16, Belgrade, Serbia.
| | - Mirjana D Pavlović
- University of Belgrade, Institute of General and Physical Chemistry, Studentski trg 12/V, Belgrade, Serbia.
| | - Davorka R Jandrlić
- University of Belgrade, Faculty of Mechanical Engineering, Kraljice Marije 16, Belgrade, Serbia.
| |
Collapse
|
3
|
Evolutionary history of the cancer immunity antigen MAGE gene family. PLoS One 2011; 6:e20365. [PMID: 21695252 PMCID: PMC3112145 DOI: 10.1371/journal.pone.0020365] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2011] [Accepted: 04/18/2011] [Indexed: 11/29/2022] Open
Abstract
The evolutionary mode of a multi-gene family can change over time, depending on the functional differentiation and local genomic environment of family members. In this study, we demonstrate such a change in the melanoma antigen (MAGE) gene family on the mammalian X chromosome. The MAGE gene family is composed of ten subfamilies that can be categorized into two types. Type I genes are of relatively recent origin, and they encode epitopes for human leukocyte antigen (HLA) in cancer cells. Type II genes are relatively ancient and some of their products are known to be involved in apoptosis or cell proliferation. The evolutionary history of the MAGE gene family can be divided into four phases. In phase I, a single-copy state of an ancestral gene and the evolutionarily conserved mode had lasted until the emergence of eutherian mammals. In phase II, eight subfamily ancestors, with the exception for MAGE-C and MAGE-D subfamilies, were formed via retrotransposition independently. This would coincide with a transposition burst of LINE elements at the eutherian radiation. However, MAGE-C was generated by gene duplication of MAGE-A. Phase III is characterized by extensive gene duplication within each subfamily and in particular the formation of palindromes in the MAGE-A subfamily, which occurred in an ancestor of the Catarrhini. Phase IV is characterized by the decay of a palindrome in most Catarrhini, with the exception of humans. Although the palindrome is truncated by frequent deletions in apes and Old World monkeys, it is retained in humans. Here, we argue that this human-specific retention stems from negative selection acting on MAGE-A genes encoding epitopes of cancer cells, which preserves their ability to bind to highly divergent HLA molecules. These findings are interpreted with consideration of the biological factors shaping recent human MAGE-A genes.
Collapse
|
4
|
Yin B, Liu G, Wang XS, Zhang H, Song YS, Wu B. Expression profile of cancer-testis genes in transitional cell carcinoma of the bladder. Urol Oncol 2011; 30:886-92. [PMID: 21396841 DOI: 10.1016/j.urolonc.2010.08.017] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2010] [Revised: 08/11/2010] [Accepted: 08/18/2010] [Indexed: 01/27/2023]
Abstract
OBJECTIVES To explore the expression profile of multiple cancer testis (CT) genes in transitional cell carcinoma of bladder (TCC), and investigate its possible correlation with clinicopathologic characteristics. METHODS The mRNA expression of 6 CT genes was detected using reverse transcription polymerase chain reaction (RT-PCR) for 102 TCC samples (59 Ta-T1, 43 T2-T4, 44 G1, 32 G2, and 26 G3 samples) as well as the matching adjacent normal bladder mucosa for each sample. The MAGE-A3 protein expression was also determined by immunoblotting. Immunohistochemistry was performed in selected samples to confirm the MAGE-A3 protein expression. RESULTS The mRNA expression of all 6 CT genes was detected with relatively high frequencies in TCC tissues. The percent of samples positive for each gene in the TCC samples are: MAGE-A3, 58.8%; MAGE-A1, 56.9%; cTAGE-1, 52.9%; MAGE-A12, 51%; cTAGE-2, 49%; and NY-ESO-1, 45.1%. Furthermore, MAGE-A3 protein expression was positive in 52.9% of TCC tissues by immunoblotting. Immunohistochemistry showed an exclusively cytoplasmic staining pattern of MAGE-A3 protein. Neither CT gene mRNA expression nor MAGE-A3 protein expression was found in the adjacent normal tissue. There was no significant correlation between CT gene expression and clinicopathologic characteristics (P > 0.05). CONCLUSIONS All six CT genes are highly expressed in TCC, and may serve as therapeutic targets of specific immunotherapy for TCC, especially in multi-antigen vaccine preparations.
Collapse
Affiliation(s)
- Bo Yin
- Department of Urology, Shengjing Hospital of China Medical University, Shenyang 110004, China.
| | | | | | | | | | | |
Collapse
|
5
|
Cesson V, Rivals JP, Escher A, Piotet E, Thielemans K, Posevitz V, Dojcinovic D, Monnier P, Speiser D, Bron L, Romero P. MAGE-A3 and MAGE-A4 specific CD4(+) T cells in head and neck cancer patients: detection of naturally acquired responses and identification of new epitopes. Cancer Immunol Immunother 2011; 60:23-35. [PMID: 20857101 PMCID: PMC11028544 DOI: 10.1007/s00262-010-0916-z] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2010] [Accepted: 08/31/2010] [Indexed: 12/13/2022]
Abstract
Frequent expression of cancer testis antigens (CTA) has been consistently observed in head and neck squamous cell carcinomas (HNSCC). For instance, in 52 HNSCC patients, MAGE-A3 and -A4 CTA were expressed in over 75% of tumors, regardless of the sites of primary tumors such as oral cavity or hypopharynx. Yet, T-cell responses against these CTA in tumor-bearing patients have not been investigated in detail. In this study, we assessed the naturally acquired T-cell response against MAGE-A3 and -A4 in nonvaccinated HNSCC patients. Autologous antigen-presenting cells pulsed with overlapping peptide pools were used to detect and isolate MAGE-A3 and MAGE-A4 specific CD4(+) T cells from healthy donors and seven head and neck cancer patients. CD4(+) T-cell clones were characterized by cytokine secretion. We could detect and isolate MAGE-A3 and MAGE-A4 specific CD4(+) T cells from 7/7 cancer patients analyzed. Moreover, we identified six previously described and three new epitopes for MAGE-A3. Among them, the MAGE-A3(111-125) and MAGE-A3(161-175) epitopes were shown to be naturally processed and presented by DC in association with HLA-DP and DR, respectively. All of the detected MAGE-A4 responses were specific for new helper epitopes. These data suggest that naturally acquired CD4(+) T-cell responses against CT antigens often occur in vivo in HNSCC cancer patients and provide a rationale for the development of active immunotherapeutic approaches in this type of tumor.
Collapse
Affiliation(s)
- Valérie Cesson
- Ludwig Institute for Cancer Research Ltd., Lausanne Branch, University Hospital (CHUV), Hôpital Orthopédique Niv. 5, aile est, Av. Pierre Decker 4, 1011 Lausanne, Switzerland
| | - Jean-Paul Rivals
- Service of Head and Neck Surgery, University Hospital, Lausanne, Switzerland
| | - Anette Escher
- Service of Head and Neck Surgery, University Hospital, Lausanne, Switzerland
| | - Elsa Piotet
- Service of Head and Neck Surgery, University Hospital, Lausanne, Switzerland
| | - Kris Thielemans
- Department of Physiology-Immunology, Medical School of the Vrje Universiteit Brussel, Brussels, Belgium
| | - Vilmos Posevitz
- Ludwig Institute for Cancer Research Ltd., Lausanne Branch, University Hospital (CHUV), Hôpital Orthopédique Niv. 5, aile est, Av. Pierre Decker 4, 1011 Lausanne, Switzerland
| | - Danijel Dojcinovic
- Ludwig Institute for Cancer Research Ltd., Lausanne Branch, 1066 Epalinges, Switzerland
| | - Philippe Monnier
- Service of Head and Neck Surgery, University Hospital, Lausanne, Switzerland
| | - Daniel Speiser
- Ludwig Institute for Cancer Research Ltd., Lausanne Branch, University Hospital (CHUV), Hôpital Orthopédique Niv. 5, aile est, Av. Pierre Decker 4, 1011 Lausanne, Switzerland
| | - Luc Bron
- Service of Head and Neck Surgery, University Hospital, Lausanne, Switzerland
| | - Pedro Romero
- Ludwig Institute for Cancer Research Ltd., Lausanne Branch, University Hospital (CHUV), Hôpital Orthopédique Niv. 5, aile est, Av. Pierre Decker 4, 1011 Lausanne, Switzerland
| |
Collapse
|
6
|
Marturano J, Longhi R, Russo V, Protti MP. Endosomal proteases influence the repertoire of MAGE-A3 epitopes recognized in vivo by CD4+ T cells. Cancer Res 2008; 68:1555-62. [PMID: 18316621 DOI: 10.1158/0008-5472.can-07-5233] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Little is known about the repertoire of MAGE-A3 CD4(+) T-cell epitopes recognized in vivo by neoplastic patients and how antigen processing influences epitope formation. Here, we first show that MAGE-A3-specific CD4(+) T cells are present in the blood of advanced melanoma patients. MAGE-A3(111-125), MAGE-A3(191-205), and MAGE-A3(281-300) were recognized by 7, 6, and 5 of the 11 patients tested, respectively. MAGE-A3(146-160) and MAGE-A3(171-185) were also recognized in two and one cases, whereas no recognition of MAGE-A3(161-175) and MAGE-A3(243-258) was observed. Cytokines produced were mainly interleukin 5 and/or granulocyte macrophage colony-stimulating factor, suggesting impairment of productive polarized Th1 responses. Secondly, proteases inhibitors were used to modulate in vitro the recognition by CD4(+) T-cells clones of dendritic cells loaded with MAGE-A3-expressing cell lysates. We found that formation of MAGE-A3(111-125) depended on both leupeptin-sensitive and pepstatin-sensitive proteases. In contrast, we found that MAGE-A3(161-175), which was never recognized ex vivo, was formed by leupeptin but destroyed by pepstatin-sensitive proteases. Collectively, our results show that (a) anti-MAGE-A3 CD4(+) T-cell immunity develops in vivo in neoplastic patients and is focused toward immunodominant epitopes, (b) the response in advanced disease is skewed toward a Th2 type, and (c) endosomal/lysosomal proteases in dendritic cells influence the repertoire of the epitopes recognized.
Collapse
Affiliation(s)
- Jill Marturano
- Department of Oncology, Scientific Institute H. San Raffaele, Milan, Italy
| | | | | | | |
Collapse
|